MECP2 and triple-negative breast carcinoma: Moreover, MeCP2 has been reported to be amplified in diverse cancer including human triple-negative breast cancers (TNBC), and it activates growth factor pathways targeted by activated Ras, MAPK and PI3K pathways (42).